
|Articles|November 15, 2002
DTC Advertising: Friend or Foe?
Direct-to-consumer advertising in U.S. healthcare is at both a zenith and crossroads where capitalism meets the ethical practice of medicine. DTC spending has never been higher, rising steadily since the U.S. Food and Drug Administration approved the tactic in 1997.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
5











